Drugmaker fined for 'excessive pricing' of rare disease drugs; biotechs worth less than their checking accounts

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: Italian authorities fine drugmaker for 'excessive' pricing of a rare disease drug By Ed Silverman Adobe Antitrust regulators in Italy have fined a drugmaker nearly $3.8 million for years of “excessive” price hikes on a rare disease medicine. Read More STAT+: More and more biotechs are worth less than their checking accounts By Damian Garde Adobe The analysts at Evercore ISI identified companies whose enterprise value is $100 million or more below zero. Read More STAT+: Justice Department says sweeping lab test fraud in Texas involved dozens of doctors and front companies By Tara Bannow Adobe A DOJ complaint describes a sweeping fraud scheme in Texas involving dozens of doctors and front companies. Read More Sponsor content by Janssen Research & Development, LLC. Pioneering precision in neuroscience We are living in an era of precision medicine, where scientific innovations have improved drug targeting across various patient populations and most therapeutic areas. However, within neuroscience, the growing unmet needs, everchanging landscape, and complex biology of neurological and neuropsychiatric disorders have made precision medicine difficult to apply. At Janssen, researchers aim to lead the neuroscience revolution to reduce the burden and disability caused by neuropsychiatric, neurological, and neurodegenerative diseases. Read the article here. STAT+: A 'dark horse' emerges in the DNA sequencing race, boasting a $100 genome By Jonathan Wosen Adobe A $100 genome would represent a major drop in price, one that could help researchers unlock the mysteries of DNA. Read More Wednesday, June 1, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser